VKTX

Viking TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$55.00

Analysis reference price unavailable

Analysis 2026-08-03 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$31.00

Analysis reference price unavailable

Analysis 2026-08-03 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$20.00

Analysis reference price unavailable

Analysis 2026-08-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-03

AI commentary

The company source confirms the Q2 print, full VANQUISH enrollment, Q3 maintenance data, Q4 oral Phase 3 plans, and $502 million cash. Stored earnings context reports a $0.11 EPS beat despite wider losses. TipRanks reports the stock fell 0.957% after the earnings report and lists selected post-print Buy reiterations, including H.C. Wainwright; broad analyst revision breadth remains unavailable. Sources: https://www.tipranks.com/stocks/vktx and https://www.marketbeat.com/earnings/reports/2026-7-29-viking-therapeutics-inc-stock/.

RankAlpha Sentiment Codex - 2026-08-03

Open post-earnings memo

Evidence flagged

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-08-31catalystQ2 EPS beat but losses widened and cash declinedHigh impact

Viking's July 29 earnings release and 8-K reported second-quarter results and $502 million in cash, equivalents, and short-term investments. Stored earnings context reports a $1.10 loss per share versus a $1.21 consensus loss, while the loss widened year over year and R&D spending increased. [#SEC-8K-2026-07-29] [#PR-EARNINGS-2026-07-30] Company IR source: https://ir.vikingtherapeutics.com/2026-07-29-Viking-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update

2026-09-30eventVK2735 maintenance-dosing data expected in Q3 2026High impact

Viking says its maintenance-dosing study is progressing and expects results in Q3 2026; the data could influence dosing flexibility and long-term commercialization potential. [#SEC-8K-2026-07-29]

2026-12-31eventOral VK2735 Phase 3 initiation expected in Q4 2026High impact

The company expects to initiate Phase 3 trials for oral VK2735 in the fourth quarter, adding an important development milestone but also execution and regulatory risk. [#SEC-8K-2026-07-29]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-03 • Updated nightlySource: Internal modelMethodology